Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5153)
All Articles published online
|
Publishing Process of This Article
|
Jul 7, 2014 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chen GY, Zhu MF, Zheng DL, Bao YT, Wang J, Zhou X, Lou GQ. Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients. World J Gastroenterol 2014; 20(25): 8195-8200 [PMID: 25009392 DOI: 10.3748/wjg.v20.i25.8195] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i25/8195.htm |
| Number | Citing Articles |
| 1 |
Michelle Martinot‐Peignoux, Tarik Asselah, Patrick Marcellin. HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients. Liver International 2015; 35(s1): 82 doi: 10.1111/liv.12735
|
| 2 |
Feng-Ping Wu, Ying Yang, Mei Li, Yi-Xin Liu, Ya-Ping Li, Wen-Jun Wang, Juan-Juan Shi, Xin Zhang, Xiao-Li Jia, Shuang-Suo Dang. Add-on pegylated interferon augments hepatitis B surface antigen clearance <i>vs</i> continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study. World Journal of Gastroenterology 2020; 26(13): 1525-1539 doi: 10.3748/wjg.v26.i13.1525
|
| 3 |
Jin Li, Xiaonan Zhang, Liang Chen, Zhanqing Zhang, Jiming Zhang, Weixia Wang, Min Wu, Bisheng Shi, Xinxin Zhang, Maya Kozlowski, Yunwen Hu, Zhenghong Yuan. Circulating miR-210 and miR-22 combined with ALT predict the virological response to interferon-alpha therapy of CHB patients. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-15594-0
|
| 4 |
Bikrant Bihari Lal, Vikrant Sood, Rajeev Khanna, Dinesh Rawat, Sanjeev Verma, Seema Alam. Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B—First study in children. Indian Journal of Gastroenterology 2018; 37(4): 326 doi: 10.1007/s12664-018-0878-1
|
| 5 |
Michelle Martinot‐Peignoux, Patrick Marcellin. Virological and serological tools to optimize the management of patients with chronic hepatitis B. Liver International 2016; 36(S1): 78 doi: 10.1111/liv.12998
|
| 6 |
Roland Kratzer, Benoît Sansas, Karine Lélu, Alexei Evlachev, Doris Schmitt, Nathalie Silvestre, Geneviève Inchauspé, Perrine Martin. A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model. Human Vaccines & Immunotherapeutics 2018; 14(6): 1417 doi: 10.1080/21645515.2018.1433970
|
| 7 |
Man-Fung Yuen, Seng-Gee Lim, Robert Plesniak, Keiji Tsuji, Harry L.A. Janssen, Cristina Pojoga, Adrian Gadano, Corneliu P. Popescu, Tatyana Stepanova, Tarik Asselah, Gheorghe Diaconescu, Hyung Joon Yim, Jeong Heo, Ewa Janczewska, Alexander Wong, Nevin Idriz, Michio Imamura, Giuliano Rizzardini, Koichi Takaguchi, Pietro Andreone, Manuela Arbune, Jinlin Hou, Sung Jae Park, Andrei Vata, Jennifer Cremer, Robert Elston, Tamara Lukić, Geoff Quinn, Lauren Maynard, Stuart Kendrick, Helene Plein, Fiona Campbell, Melanie Paff, Dickens Theodore. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. New England Journal of Medicine 2022; 387(21): 1957 doi: 10.1056/NEJMoa2210027
|
| 8 |
Shuai Wu, Wenfan Luo, Yin Wu, Hongjie Chen, Jie Peng. HBsAg quantification predicts off-treatment response to interferon in chronic hepatitis B patients: a retrospective study of 250 cases. BMC Gastroenterology 2020; 20(1) doi: 10.1186/s12876-020-01263-6
|
| 9 |
Xia-Xia Zhang, Min-Ran Li, Hong-Li Xi, Ying Cao, Ren-Wen Zhang, Yu Zhang, Xiao-Yuan Xu. Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy. Chinese Medical Journal 2016; 129(8): 929 doi: 10.4103/0366-6999.179802
|
| 10 |
Ming‐Yu Zhu, Pei‐Zhan Chen, Jing Li, De‐Min Yu, Dao Huang, Xue‐Juan Zhu, Yue Han, Jie Chen, Wei Huang, Yong‐Yan Chen, Qi‐Ming Gong, Jie‐Hong Jiang, Dong‐Hua Zhang, Yan Zhang, Ji‐Ming Zhang, Xin‐Xin Zhang. Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon‐α treatment in HBeAg‐positive chronic hepatitis B patients. Journal of Medical Virology 2018; 90(4): 721 doi: 10.1002/jmv.25010
|
| 11 |
Jing Huang, Ka Zhang, Wenli Chen, Jinyao Liao, Xiaodan Luo, Ren Chen. Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-13747-9
|
| 12 |
Xiongyue Cao, Qiankun Hu, Wei Xu, Qiang Li, Jiming Zhang, Liang Chen, Yuxian Huang, Xun Qi. Kinetics changes in total cholesterol predict HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon‐alfa. Journal of Viral Hepatitis 2023; 30(4): 310 doi: 10.1111/jvh.13787
|
| 13 |
Phunchai Charatcharoenwitthaya, Apichat Kaewdech, Teerha Piratvisuth. Controversies in Treating Chronic HBV. Clinics in Liver Disease 2021; 25(4): 741 doi: 10.1016/j.cld.2021.06.004
|
| 14 |
Yin-Chen Wang, Sien-Sing Yang, Chien-Wei Su, Yuan-Jen Wang, Kuei-Chuan Lee, Teh-Ia Huo, Han-Chieh Lin, Yi-Hsiang Huang. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. Scientific Reports 2016; 6(1) doi: 10.1038/srep29605
|